Atezolizumab,Bevacizumab
Roche
[]
the pivotal phase iii imbrave050 of adjuvant atezo/bev in high-risk hcc is positive!!! this is exciting for our patients! way to start #gi23. 
GI Oncologist @MayoCancerCare| Alumni: @MayoHemeOnc’21, @penn_state Med'15 & IM'18 l Interests: Translational Immuno-Oncology, Developmental Therapeutics.